Guardant Health: ESMO Open publishes PRECISION results; Guardant360 detects genomic alterations in 97% of patients

Guardant Health announced that ESMO Open has published results from PRECISION, a prospective multicenter observational trial in Japan of 130 patients evaluating blood-based testing for recurrence risk after curative-intent surgery for colorectal cancer metastases. Guardant360 detected genomic alterations in 97% of patients.

Detected & updated continuously · Source: Nebula